Summit Global Investments Has $7.21 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Global Investments cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,114 shares of the biopharmaceutical company's stock after selling 1,754 shares during the period. Summit Global Investments' holdings in Regeneron Pharmaceuticals were worth $7,205,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Willner & Heller LLC boosted its position in Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after purchasing an additional 15 shares during the period. OLD Second National Bank of Aurora boosted its holdings in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after buying an additional 15 shares during the period. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares during the period. Finally, Manchester Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 18 shares during the period. 83.31% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

REGN has been the topic of several research reports. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 4th. Finally, Citigroup lowered their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $6.00 during mid-day trading on Wednesday, reaching $640.14. The company had a trading volume of 1,251,813 shares, compared to its average volume of 639,898. The company has a market capitalization of $69.98 billion, a price-to-earnings ratio of 16.72, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company's 50 day simple moving average is $687.18 and its 200 day simple moving average is $806.20. Regeneron Pharmaceuticals, Inc. has a 1-year low of $630.62 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $11.86 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. Regeneron Pharmaceuticals's payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.